Ondo Finance has introduced on-chain tokenization products that provide access to private equity, specifically targeting an AI company in the pre-IPO stage. This move expands Ondo's tokenization from public market instruments to private equity, traditionally limited to institutional investors. The tokenized products aim to bring pre-IPO equity onto blockchain infrastructure, potentially allowing smaller investors to access high-growth AI company shares. Key details such as the AI company's identity, offering size, investor eligibility, and jurisdictions remain unconfirmed, with further announcements expected to clarify these aspects.
Ondo Finance's launch of tokenized private equity products comes as a backdrop to a mixed cryptocurrency market on Pluang. For readers following digital assets, here is Pluang's market snapshot as of Oct 06, 2026 12:41 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell. Notably, Compound (COMP) traded at Rp439.483 with a 20% sell and 80% buy split and a typical hold time of 97 days, Enjin Coin (ENJ) at Rp591 with 72% sell and 28% buy activity, and Fantom (FTM) at Rp11.382 with a typical hold time of 87 days.
Ethereum (ETH) maintained stability above $2,700, marking its first weekly close above this level in nine months, signaling renewed bullish sentiment. Treasury firm BitMine expanded its Ethereum holdings by 15,112 ETH, now controlling about 4.9% of t...
Bitcoin options markets have shifted toward a bullish stance, with one-week 25-delta call options now more in demand than puts, indicating traders expect price gains. This shift, first seen in August 2026, shows calls making up about 61.4% of open in...
Binance experienced a net outflow of approximately 40,000 Bitcoin over a 15-day period, reducing its reserves from 704,800 BTC to 663,100 BTC. The weekly net outflow hit 23,100 BTC, the highest since June 2023, with a daily peak of 14,300 BTC on Octo...
Nebius Group N.V. is rated a buy due to its strategic partnership with Palantir, which positions Nebius as the preferred sovereign infrastructure provider for Palantir's enterprise AI solutions targeting regulated industries. This collaboration allow...
Poolbeg Pharma has obtained a South Korean patent for POLB 001, a treatment designed to prevent cytokine release syndrome (CRS), a serious side effect of cancer immunotherapy. The patent covers the use of p38 MAP kinase inhibitors to prevent CRS and ...
